No results for ‘’
Samrat Pharmachem Ltd
₹225.95
(0.67%)
Thu, 24 Sept 2026, 05:46 am
Process Industries
Chemicals: Specialty
24.5KSamrat Pharmachem Ratios
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 3.84 | 4.21 | 2.46 | 16.15 | 25.90 | 36.08 | 27.50 | 13.91 | 12.15 | 15.02 | 4.37 | 7.88 | 8.72 | 6.89 | 47.64 | 13.59 |
| Price to book ratio | 0.39 | 0.59 | 0.65 | 0.74 | 0.50 | 0.48 | 0.85 | 0.61 | 1.59 | 2.11 | 1.15 | 0.76 | 1.42 | 3.20 | 1.82 | 1.59 | 1.35 |
| Price to sales ratio | 0.07 | 0.10 | 0.13 | 0.13 | 0.09 | 0.10 | 0.24 | 0.13 | 0.34 | 0.42 | 0.21 | 0.13 | 0.23 | 0.68 | 0.37 | 0.37 | 0.34 |
| Price to cash flow ratio | 5.78 | 4.71 | 0 | 2.34 | 0 | 1.53 | 0 | 6.43 | 0 | 0 | 16.28 | 0 | 11.56 | 8.84 | 0 | 11.34 | 0 |
| Enterprise value | 1.87Cr | 2.91Cr | 5.78Cr | 8.26Cr | 8.23Cr | 5.03Cr | 10.68Cr | 8.39Cr | 24.19Cr | 44.49Cr | 27.35Cr | 26.74Cr | 48.27Cr | 143Cr | 121Cr | 102Cr | 106Cr |
| Enterprise value to EBITDA ratio | 4.22 | 1.51 | 2.40 | 1.38 | 7.63 | 8.35 | 9.13 | 7 | 6.54 | 7.57 | 8.67 | 4.06 | 5.40 | 5.85 | 5.02 | 36.10 | 9.94 |
| Debt to equity ratio | 0.38 | 0.22 | 0.22 | 0.27 | 0.35 | 0.24 | 0.24 | 0.40 | 0.45 | 0.51 | 0.33 | 0.39 | 0.30 | 0.16 | 0.30 | 0.13 | 0.14 |
| Return on equity % | 0 | 16.54 | 16.68 | 35.61 | 3.15 | 1.86 | 2.38 | 2.21 | 12.07 | 19 | 7.96 | 19.10 | 19.77 | 44.95 | 30.25 | 3.38 | 10.40 |
Samrat Pharmachem Ltd Ratios
The Samrat Pharmachem Ltd Ratios page provides a complete fundamental analysis of Samrat Pharmachem Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Samrat Pharmachem Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Samrat Pharmachem Ltd (NSE: , BSE: 530125) is currently trading at ₹225.95, with a market capitalization of ₹69.35Cr. As a major player in the Process industries sector and Chemicals: specialty industry, Samrat Pharmachem Ltd remains a key stock for fundamental analysis using Samrat Pharmachem Ltd Ratios.
Samrat Pharmachem Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Samrat Pharmachem Ltd P/E ratio currently stands at 13.59, making it one of the most tracked metrics in Samrat Pharmachem Ltd Ratios.
Historically, the Samrat Pharmachem Ltd P/E ratio has shown strong fluctuations:
- 2024: 13.59
- 2023: 47.64
- 2022: 6.89
- 2021: 8.72
- 2020: 7.88
The decline in Samrat Pharmachem Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Samrat Pharmachem Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.35.
Historical P/B trend:
- 2024: 1.35
- 2023: 1.59
- 2022: 1.82
- 2021: 3.20
Samrat Pharmachem Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Samrat Pharmachem Ltd P/S ratio currently stands at 0.34, an important part of Samrat Pharmachem Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 0.34
- 2023: 0.37
- 2022: 0.37
- 2021: 0.68
A stable or declining Samrat Pharmachem Ltd P/S ratio indicates cautious market sentiment.
Samrat Pharmachem Ltd Price to Cash Flow Ratio (P/CF)
The Samrat Pharmachem Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.
Historical Samrat Pharmachem Ltd Price to Cash Flow Ratio:
- 2024: 0
- 2023: 11.34
- 2022: 0
- 2021: 8.84
- 2020: 11.56
The declining Samrat Pharmachem Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Samrat Pharmachem Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Samrat Pharmachem Ltd EV currently stands at ₹106Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 106Cr
- 2023: 102Cr
- 2022: 121Cr
- 2021: 143Cr
Samrat Pharmachem Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Samrat Pharmachem Ltd EV/EBITDA ratio is currently 9.94, a key metric in Samrat Pharmachem Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 9.94
- 2023: 36.10
- 2022: 5.02
- 2021: 5.85
Stable Samrat Pharmachem Ltd EV/EBITDA indicates balanced valuation.
Samrat Pharmachem Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Samrat Pharmachem Ltd D/E ratio is currently 0.14, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.14
- 2023: 0.13
- 2022: 0.30
- 2021: 0.16
Samrat Pharmachem Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Samrat Pharmachem Ltd ROE currently stands at 10.40%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 10.40
- 2023: 3.38
- 2022: 30.25
- 2021: 44.95
Samrat Pharmachem Ltd maintains stable profitability levels.
Samrat Pharmachem Ltd Ratios Analysis Summary
The Samrat Pharmachem Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Samrat Pharmachem Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Samrat Pharmachem Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.